eligibility_summary
Incl: adults 18–75, treatment‑naïve, path‑confirmed PMBCL (stage I–IV, IPI 0–5), measurable disease, ECOG 0–2, adequate organ function, >12‑mo survival, contraception and negative pregnancy test if WOCBP. Excl: CNS lymphoma, prior ICIs, severe mAb allergy, autoimmune needing systemic therapy, recent immunosuppression or anti‑cancer therapy/surgery/RT, recent live vaccine/herbal, HIV/HBV/HCV, active infection, pregnancy/lactation, uncontrolled comorbidity or significant psychiatric/incapacity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II, single-arm trial in untreated primary mediastinal DLBCL tests: (1) Sintilimab, an anti–PD-1 monoclonal antibody (checkpoint inhibitor) to restore T‑cell antitumor activity, plus rituximab, an anti‑CD20 monoclonal antibody that depletes B cells via ADCC/CDC/apoptosis, followed by (2) response-adapted R-CHOP chemotherapy: cyclophosphamide (alkylating DNA crosslinker), doxorubicin (anthracycline/topoisomerase II inhibitor), vincristine (microtubule inhibitor), and prednisone (glucocorticoid inducing lymphocyte apoptosis), and (3) maintenance nintedanib, an oral multikinase TKI inhibiting VEGFR/FGFR/PDGFR (anti-angiogenic). Targets: PD‑1/PD‑L1 axis, CD20+ malignant B cells, DNA/topo II, microtubules, glucocorticoid receptor pathways, and tumor angiogenesis.